Prize-Winner of the program « Investments for the Future » 2011 in the "preindustrial demonstrators" category, MI-mAbs was established by Aix-Marseille Université (AMU) and its private subsidiary Protisvalor, CNRS, Inserm, the Institute Paoli-Calmettes (IPC), 3 of their research centers (the Centre d’Immunologie de Marseille-Luminy, the Cancer Research Center of Marseille and the Centre for Immunophenomics), the European leader in immuno-oncology, Innate Pharma and Sanofi, one of the world leaders in health.
Besides its know-how regarding immunotechnology, MI-mAbs also benefits from the complementary expertise of his founders:
AMU is the project administrative coordinator.
CIML ensures the scientific coordination of Mi-mAbs (under the administrative responsibility of AMU) and offers its expertise in immunology, immunopathology and a wide range of technologies dedicated to antibody production (generation of mouse and rat monoclonal antibodies.)
CRCM provides new targets and tumor models for in vitro and in vivo validation
IPC gives access to its library of tumors samples
CIPHE contributes to the design of in vivo models of the relevant diseases
Innate Pharma brings its expertise and experience in monoclonal antibody engineering and immunopharmacology.
Sanofi puts at disposal of Mi-mAbs staff and its capacity of production for recombinant proteins, as well as its experience in biological drug development.
In addition, Mi-mAbs will benefit from access to the future inflammatory tissue bank, which will be implemented by the Assistance-Publique Hospitals of Marseille with the support of Marseille Immunopole.
This continuum of expertise brought together in Mi-mAbs is at the heart of the strategy of Marseille Immunopole (MI), the 3rd cluster of the competitive cluster for health Eurobiomed. Its mission: accelerate the development of new immune-based therapies, including monoclonal antibodies, the primary class of drugs in oncology.